Infectious encephalitis diagnosis and treatment in immunosupressed patients: a case report and review of literature by M. Jokubaitis, J. Valaikienė

“…This article describes an atypical clinical case of a bacterial meningoencephalitis with stroke-like symptoms in a patient with multiple myeloma. In addition, the article reviews clinical presentation, diagnostic and treatment recommendations of infectious encephalitis in immunosuppressed patients. …”
Get full text

A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone by Jew Win Kuan, Sing Ling Chai, Pathmanathan Rajadurai, Lee Gong Lau, Joseph Uchang, Sharifah Noor Akmal Syed Husain

“…Central nervous system (CNS) involvement in multiple myeloma (MM) (MM-CNS) in the form of leptomeningeal myelomatosis or brain parenchyma plasmacytoma is rare, causing challenges in clinical diagnosis and treatment. …”
Get full text

Ulcerative Colitis in Hematological Malignancies: Paraneoplastic Manifestation or Coincidental Bystander? by Gregorios Christodoulidis, Konstantinos Perivoliotis, Anastasios Manolakis, Alexandros Diamantis, Apostolos Koffas, Dimitrios Magouliotis, Vasiliki Pappi, Dimitrios Zacharoulis

“…Evidence of coexistence of diverse hematological malignancies—lymphoma, leukemia, multiple myeloma, and myelodysplastic syndromes—and either ulcerative colitis or Crohn’s disease can be found in the literature. …”
Get full text

A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma by Heather Katz, Mina Shenouda, Deena Dahshan, George Sonnier, Yehuda Lebowicz

“…We describe a case of a 74-year-old man with relapsed multiple myeloma who was started on ixazomib, lenalidomide, and dexamethasone. …”
Get full text

Emerging Stem Cell Therapies: Treatment, Safety, and Biology by Joel Sng, Thomas Lufkin

“…Hematopoietic stem cell transplantation was the first example of a successful stem cell therapy and is widely utilized for treating various diseases including adult T-cell leukemia-lymphoma and multiple myeloma. The autologous transplantation of mesenchymal stem cells is increasingly employed to catalyze the repair of mesenchymal tissue and others, including the lung and heart, and utilized in treating various conditions such as stroke, multiple sclerosis, and diabetes. …”
Get full text

Coordinate Descent-Based Sparse Nonnegative Matrix Factorization for Robust Cancer-Class Discovery and Microarray Data Analysis by Melisew Tefera Belachew

“…We test this algorithm on two well-known cancer datasets: leukemia and multiple myeloma. The numerical results indicate that the proposed algorithm performs significantly better than related state-of-the-art methods. …”
Get full text

Imaging of a Case of Extramedullary Solitary Plasmacytoma of the Trachea by M. Garelli, C. Righini, C. Faure, A. Jankowski, C. Brambilla, G. R. Ferretti

“…Relevant investigations excluded multiple myeloma. Follow-up CT showed persistent thickening of the tracheal wall, but there has been no recurrence after one-year followup.…”
Get full text

Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Man with Fragile X-associated Tremor/Ataxia Syndrome by Tanjung A. Sumekar, Aneel A. Ashrani, Tri I. Winarni, Randi J. Hagerman

“…We report the clinical presentation and laboratory findings of a 69-year-old man with fragile X-associated tremor ataxia syndrome (FXTAS), a progressive neurodegenerative disorder, who was noted to have monoclonal gammopathy of undetermined significance (MGUS), a plasma cell proliferative disorder and a precursor disease of multiple myeloma. Both MGUS and FXTAS are associated with microRNA (miRNA) dysregulation. …”
Get full text

Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya by Matilda Ong’ondi, Elizabeth Kagotho

“…Plasma Cell Leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasia that can arise either de novo (primary plasma cell leukemia) or evolve from previously diagnosed and treated multiple myeloma (secondary PCL). We highlight three clinical cases with very different presentations as a reminder of this diagnosis. …”
Get full text

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD by Philip T. Sobash, Achuta K. Guddati, Vamsi Kota

“…The long-term use of ruxolitinib has not been explicitly studied outside the context in the treatment of multiple myeloma. With current clinical trials underway for the use of ruxolitinib in srGVHD, there are still no current guidelines or protocols for long-term clinical use. …”
Get full text

Two Cases of Heavy Chain MGUS by Jan Van Keer, Björn Meijers, Michel Delforge, Gregor Verhoef, Koen Poesen

“…Neither patient had corresponding monoclonal light chains. Workup for multiple myeloma and lymphoma was negative in both patients. …”
Get full text

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas by Marco Gunnellini, Lorenzo Falchi

“…Lenalidomide is an immunomodulatory drug with activity in multiple myeloma, myelodisplastic syndrome and chronic lymphoproliferative disorders. …”
Get full text

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib by Manu R. Pandey, Pankit Vachhani, Evelena P. Ontiveros

“…Recently, bortezomib, a proteasome inhibitor used commonly in patients with multiple myeloma, was shown to induce remission in patients with refractory TTP. …”
Get full text

Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review by Marco Ruella, Guido Ghilardi, Zainul S. Hasanali, Sandra P. Susanibar-Adaniya, Lena E. Winestone, Alfred L. Garfall

“…We focus on B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin’s lymphoma, and multiple myeloma.…”
Get full text

Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation by Mary Nauffal, Stephen Eng, Andrew Lin, Alexander Chan, Kathryn Mazzerella, Sergio Giralt, Miguel-Angel Perales, Boglarka Gyurkocza

“…Isatuximab is an IgG1κ-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuximab. …”
Get full text

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES by Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone

“…Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells have been introduced in the therapy of B-cell lymphomas, B-ALLs and multiple myeloma. These therapeutic successes have triggered the application of CAR-T cell therapy to other hematologic tumors, including T-cell malignancies. …”
Get full text

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia) by Maroun Bou Zerdan, Jason Valent, Maria Julia Diacovo, Karl Theil, Chakra P. Chaulagain

Get full text

Obesity as a Major Risk Factor for Cancer by Giovanni De Pergola, Franco Silvestris

“…Reports from the International Agency for Research into Cancer and the World Cancer Research Fund (WCRF) have shown that the strongest evidence exists for an association of obesity with the following cancer types: endometrial, esophageal adenocarcinoma, colorectal, postmenopausal breast, prostate, and renal, whereas the less common malignancies are leukemia, non-Hodgkin’s lymphoma, multiple myeloma, malignant melanoma, and thyroid tumours. …”
Get full text

P2X7 Receptor Function in Bone-Related Cancer by Elena Adinolfi, Francesca Amoroso, Anna Lisa Giuliani

“…Search of mRNA expression microchip databases and literature analysis demonstrate a high expression of P2X7 in primary bone tumors as well as in other malignancies such as multiple myeloma, neuroblastoma, breast, and prostate cancer. …”
Get full text

ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives by Marco Folci, Giacomo Ramponi, Dana Shiffer, Aurora Zumbo, Michele Agosti, Enrico Brunetta

“…PR3-derived PR1 peptide is being studied as an immunotherapy target in leukemia and multiple myeloma. This study is aimed at bringing together various evidences from the field of immunological and hematological research, at exposing contradictions, and at revealing novel insights on the association between ANCA-associated vasculitis and hematologic malignancies.…”
Get full text